EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Manuel Pombo-Suárez, Daniel Seoane-Mato, Federico Díaz-González, Luis Cea-Calvo, Fernando Sánchez-Alonso, Marta Sánchez-Jareño, Vega Jovani, Blanca García-Magallón, Olga Martínez-González, Cristina Campos-Fernández, Javier Manero, Cesar Díaz-Torne und 4 weitere

Musculoskeletal Care · 2023-03 · 21 (1) · 189-197

DOI: 10.1002/msc.1684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Musculoskeletal Care, online erschienen am 22.08.2022. Verfasst von Manuel Pombo-Suárez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Spondylarthritis, Arthritis, Rheumatoid, Axial Spondyloarthritis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors.

Methods

Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started golimumab >6 months before the analysis for an approved indication (rheumatoid arthritis [RA], axial spondyloarthritis [SpA] or psoriatic arthritis [PsA]).

Results

Among 885 patients (RA 267, axial SpA 370, PsA 248) receiving 944 cycles of golimumab, the retention rate of golimumab was 71.1% (95% confidence interval: 68.0–73.9) at year 1% and 37.7% (95% CI: 33.3–42.1) at year 7 and at year 8. Retention was higher when golimumab was used as the first biological drug (81.7% at year 1, 49.9% at year 7, p < 0.001). In Cox regression analysis, factors associated with golimumab retention included use as first‐line therapy (hazard ratio [HR] for discontinuation 1.52 for second‐ and 1.79 for third/later‐line vs. first‐line), use in axial SpA or PsA rather than RA (HR for axial SpA vs. RA 0.59, for PsA vs. Rheumatoid arthritis 0.67), and treatment with concomitant methotrexate (HR 0.67). Factors associated with golimumab discontinuation were corticosteroid use (HR 1.46) and disease activity above median (HR 1.29) at golimumab initiation.

Conclusion

Based on this retrospective analysis of the BIOBADASER registry, nearly two‐fifths (37.7%) of adult rheumatology patients initiating golimumab will remain on treatment for 8 years, with a higher probability of retention in axial SpA or PsA indications and when golimumab is used as first biologic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticSpondylarthritisArthritis, RheumatoidAxial SpondyloarthritisAntirheumatic AgentsAdultHumansRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal

Stichwörter der Autor:innen

axial spondyloarthritisgolimumabpsoriatic arthritisrheumatoid arthritistreatment retention

Substanzen

Antirheumatic AgentsgolimumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
  • Clinical Research Unit, Spanish Society of Rheumatology (SER), Madrid, Spain.
  • Department of Rheumatology, Hospital Universitario de Canarias, Sta Cruz de Tenerife, Spain.
  • Medical Affairs, MSD Spain, Madrid, Spain.
  • Department of Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain.
  • Department of Rheumatology, Hospital San Jorge, Huesca, Spain.

Zitieren

APA

Pombo-Suárez, M., Seoane-Mato, D., Díaz-González, F., Cea-Calvo, L., Sánchez-Alonso, F., Sánchez-Jareño, M., Jovani, V., García-Magallón, B., Martínez-González, O., Campos-Fernández, C., Manero, J., Díaz-Torne, C., Bohórquez, C., Ros-Vilamajó, I., Pérez-Vera, Y., & Castrejón, I. (2023). Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. Musculoskeletal Care, 21(1), 189-197. https://doi.org/10.1002/msc.1684

Vancouver

Pombo-Suárez M, Seoane-Mato D, Díaz-González F, Cea-Calvo L, Sánchez-Alonso F, Sánchez-Jareño M, et al. Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. Musculoskeletal Care. 2023;21(1):189-197. doi:10.1002/msc.1684

BibTeX
@article{PomboSurez2023,
  author = {Pombo-Suárez, Manuel and Seoane-Mato, Daniel and Díaz-González, Federico and Cea-Calvo, Luis and Sánchez-Alonso, Fernando and Sánchez-Jareño, Marta and Jovani, Vega and García-Magallón, Blanca and Martínez-González, Olga and Campos-Fernández, Cristina and Manero, Javier and Díaz-Torne, Cesar and Bohórquez, Cristina and Ros-Vilamajó, Inmaculada and Pérez-Vera, Yanira and Castrejón, Isabel},
  title = {Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis},
  journal = {Musculoskeletal Care},
  year = {2023},
  volume = {21},
  number = {1},
  pages = {189--197},
  doi = {10.1002/msc.1684}
}
Kostenlos starten →